Next Generation Laboratories Obtain European Patent for TFN® Synthetic Nicotine Manufacturing Process, Further Strengthening Intellectual Property Enforcement Efforts Against TFN® Violators



this patent grant strengthens our intellectual property in a number of European countries, allowing the company to better enforce its rights against infringers and counterfeiters of TFN® brand synthetic nicotine

Next Generation Labs LLC, the world’s oldest and largest producer and seller of premium synthetic S, R and RS isomers, is pleased to announce that the company has been granted a European patent (Patent # 3209653) , for its exclusive technology linked to the preparation of the RS isomer nicotine.

“This patent grant by the European Patent Office is an important step for Next Generation Labs, as it strengthens our intellectual property portfolio of tobacco-free synthetic nicotine in a number of European countries, allowing the Company to better enforce its rights against offenders and counterfeiters of its industry-leading TFN® brand synthetic nicotine. Along with our announcement of patent grants in China, Australia and Canada, and the enforcement efforts of our strategic partner NextEra in South Korea, we are now even better positioned to take direct action against companies that violate our patented nicotine production process in 38 additional countries. . “

Next Generation Labs was the first company to successfully develop the bulk manufacture of innovative tobacco-free synthetic nicotine for use in new tobacco-free products, such as vaping liquids and pens, in non-scorching heat devices ( HNB) and in many oral nicotine products (MON), as well as in innovative nicotine withdrawal pharmaceuticals.

“Our society believes that consumers have the right to access non-tobacco nicotine as a matter of choice. Many adult consumers want to enjoy nicotine, but want to do so without the lingering and potentially harmful effects of long-term tobacco use. The introduction of TFN® brand synthetic nicotine has created a liberating opportunity for consumers, who, thanks to Next Generation Labs nicotine technology, are now able to completely break away from tobacco by taking advantage of many of the leading brands available. on the market today. who use TFN®.

Since its founding in early 2014, Next Generation Labs has led efforts to bring the potential promise of the synthetic S-isomer, the R-isomer, and the combinatorial R / S isomer directly to the forefront of the debate over the elimination of tobacco use in all its forms.

Additionally, with the introduction of many new non-tobacco products containing TFN® nicotine, the company and its brand development clients have placed the use of synthetic nicotine as a key ingredient in future marketing strategies. harm reduction of tobacco. As a result, Next Generation Labs expects to see wider adoption of TFN® brand synthetic nicotine products by the tobacco and vape industries, as well as increased use of Pharmanic® brand synthetic nicotine in the industry. pharmaceutical industry – as it gradually moves away from its continued addiction. on tobacco manufacturers and the nicotine extracted from tobacco currently used in smoking cessation products.

About Next Generation Labs (“NGL”): Since 2014, NGL has been the world’s largest manufacturer of S-isomer, R / S-combinatorial isomer and R-isomer of synthetic nicotine under the trademark TFN®. NGL has helped brand owners develop new tobacco-free products using TFN® nicotine that provide smokers and tobacco users with a real alternative to combustible tobacco products, as well as real alternatives to tobacco through its creation of a synthetic nicotine free from all tobacco. Unlike other nicotines, NGL’s TFN® product is devoid of any component of tobacco from the point of raw material selection to the completion of its manufacturing process. NGL’s TFN® products are manufactured under strict conditions to meet cGMP, USP and EU standards to achieve a level of 99.97% pure synthetic nicotine.

Share the article on social media or by email:


Leave A Reply